Priority Health Is First Health Plan To Cover FoundationOne And FoundationOne Heme To Enhance Precision Cancer Treatment

Foundation Medicine, Inc.

and Priority Health today announced an agreement to enhance precision medicine options for Priority Health members with advanced cancers. With this agreement, Priority Health is the first health plan in the country to cover FoundationOne and FoundationOne Heme, the most comprehensive genomic profiles currently commercially available for patients with cancer. “FoundationOne and FoundationOne Heme results empower physicians to develop an individualized treatment plan based on the unique genomic profile of each patient's tumor,” said John Fox, MD, MHA, associate vice president, medical affairs, Priority Health. “Historically, cancers were categorized and treated by location in the body: lung, breast, colon, blood, etc. With additional information available about the underlying genomic drivers of a tumor's growth, we're helping our members to access customized treatment options with targeted therapies.” Priority Health's positive coverage decision includes FoundationOne, a fully informative genomic profile that interrogates the entire coding region in 315 genes and select introns in 28 genes commonly altered in solid tumors, and FoundationOne Heme, a fully informative genomic profile that analyzes DNA in 405 genes and RNA in 265 genes that are most commonly altered in hematologic malignancies, sarcomas, and select pediatric cancers. Both services inform the appropriate utilization of targeted therapies in alignment with up-to-date medical evidence. “This positive coverage decision from a leading commercial insurer serves as further validation of the clinical utility of a treatment plan informed by comprehensive genomic profiling of a patient's unique cancer,” said Kevin Krenitsky, MD, chief commercial officer of Foundation Medicine. “Priority Health's leadership in recognizing important innovations to advance patient care marks a meaningful step in the acceptance of comprehensive genomic profiling as an important element in the clinical treatment of cancer. We look forward to working with Priority Health to define additional applications for our current and future products and services.”